RetinaCME
EXPERT VIDEOCME

Rapid Response from Chicago: Advances in the Treatment of Diabetic Retinopathy

Author(s)/Faculty: Rishi P. Singh, MD; Amy Babiuch, MD; David Eichenbaum, MD
Release Date: 11/7/2018Expiration Date: 11/6/2019
Credit Type: CMENumber of Credits: 0.75
Content Type: VideoProvider:
Diabetic retinopathy (DR) continues to be a leading cause of blindness. However, early diagnosis and prompt treatment with laser and/or intravitreal anti-vascular endothelial growth factor (VEGF) therapy has been shown to effectively prevent vision loss. Until recently, the primary approach for the management of patients with DR was using panretinal photocoagulation therapy. Additional treatment options for DR were discovered through analysis of data from studies of anti-VEGF therapy for diabetic macular edema. Since then, new information about the optimal management of diabetic retinal disease with anti-VEGF therapy has been obtained from subanalyses of those studies and their open-label extensions, as well as new clinical studies. Advances in knowledge of DR and its treatment have also been obtained from the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol S trial, which is the first randomized, controlled trial to compare the anti-VEGF agent ranibizumab with laser therapy for the treatment of proliferative DR. This CME Rapid Response activity will feature experts who will review recent clinical trial data on the treatment of proliferative and nonproliferative DR.